延长间隔磺达肝癸钠方案在严重肾功能不全危重患者中的抗Xa因子水平评估
峰浓度和谷浓度抗Xa因子水平分别为0.36±0.18 mg/L和0.17±0.11 mg/L,与肾功能正常患者每日一次常规剂量所报告水平相似;未发生下肢深静脉血栓或疑似VTE事件,2例(6%)发生显著出血事件。
要点
- 严重肾功能不全危重患者使用磺达肝癸钠2.5 mg每48小时一次,抗Xa因子水平与肾功能正常者每日一次方案相似。
- 该研究中未观察到下肢深静脉血栓或疑似VTE事件。
- 2例(6%)患者发生显著出血事件,需关注出血风险。
核心结论
- 在严重肾功能不全危重患者中,磺达肝癸钠2.5 mg每48小时一次用于VTE预防,所达到的峰、谷抗Xa因子水平与肾功能正常非危重患者每日一次给药所报告的水平相似。
主要发现
- 磺达肝癸钠峰浓度(n=98)和谷浓度(n=86)抗Xa因子水平分别为0.36±0.18 mg/L和0.17±0.11 mg/L(均值±标准差)。
- 患者接受磺达肝癸钠的中位剂量数为4次(四分位距2至5次)。
- 未发生下肢深静脉血栓或疑似VTE事件。
- 2例(6%)患者发生显著出血事件。
临床怎么用
- 对于严重肾功能不全的危重患者,当需要避免使用肝素类药物时,磺达肝癸钠2.5 mg每48小时一次可作为VTE预防的替代方案。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Pharmacologic options for venous thromboembolism (VTE) prophylaxis are often limited in critically ill patients due to thrombocytopenia and multisystem organ dysfunction. Fondaparinux offers potential advantages in the critically ill; however, it is currently contraindicated in severe renal dysfunction (SRD). We evaluated anti-factor Xa levels in critically ill patients with SRD who were receiving an extended interval dosing regimen of fondaparinux for VTE prophylaxis. METHODS: A prospective, single-arm, interventional study was conducted at two academic hospitals of the Detroit Medical Center. Eligible patients were in the intensive care unit, had an estimated creatinine clearance of less than 30 ml/minute, and had either acute kidney injury or end-stage renal disease; several patients were taking renal replacement therapy. Fondaparinux was administered at an extended interval dosing regimen of 2.5 mg subcutaneously every 48 hours. Fondaparinux peak and trough anti-factor Xa levels were obtained. Lower extremity venous duplex studies were performed at baseline and study completion to assess for deep vein thrombosis (DVT), and patients were monitored for bleeding complications. RESULTS: Thirty-two patients were enrolled. Patients received a median of four doses (interquartile range two to five) of fondaparinux. Fondaparinux peak (n=98) and trough (n=86) anti-factor Xa levels were 0.36 ± 0.18 mg/L and 0.17 ± 0.11 mg/L (mean ± SD), respectively, and were similar to levels reported in patients with normal renal function receiving conventional once-daily dosing. No lower extremity DVTs or suspected VTE events occurred. Two (6%) patients had significant bleeding events. CONCLUSIONS: In critically ill patients with SRD, an extended interval fondaparinux dosing regimen of 2.5 mg every 48 hours for VTE prophylaxis achieved peak and trough anti-factor Xa levels similar to those reported in noncritically ill patients with normal renal function receiving once-daily fondaparinux. This regimen offers an alternative for patients with SRD when heparinoids must be avoided.
引用
- Wahby KA, Riley LK, Tennenberg SD, et al. Assessment of an Extended Interval Fondaparinux Dosing Regimen for Venous Thromboembolism Prophylaxis in Critically Ill Patients with Severe Renal Dysfunction Using Antifactor Xa Levels. Pharmacotherapy. 2017. PMID: 28833353. doi:10.1002/phar.2014
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。